Mouse models suggest a cooperative role between TET2 and RHOA in AITL lymphomagenesis and indicate in the RHOA-dependent activation of ICOS-PI3K pathway, a targetable vulnerability for targeted therapies [36,39]. This evidence concerns the gene ICOS and angioimmunoblastic T-cell lymphoma.